Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology Co., Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the possibility of declaring an interim dividend, which could impact shareholder returns and reflect the company’s financial health.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and production of biological materials and medical devices. The company is based in China and is known for its innovative solutions in healthcare, particularly in ophthalmology, orthopedics, and medical aesthetics.
Average Trading Volume: 702,965
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.78B
For detailed information about 6826 stock, go to TipRanks’ Stock Analysis page.